Photo from Elizabeth Budde/X
Apr 8, 2024, 08:41
Elizabeth Budde: We reported the longest follow-up of using BsAbs in lymphoma
Elizabeth Budde, Associate Professor at City of Hope, shared on X/Twitter:
“We reported the longest follow-up of using BsAbs in lymphoma. With a median 3.5 years follow-up, the DOCR for patients treated with mosunetuzumab is not reached. No relapses post 26 months. Retreatment worked in 10/12 including 7 complete remissions.”
Proceed to the article.
Source: Elizabeth Budde/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 20:38
Nov 20, 2024, 20:27
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12
Nov 20, 2024, 19:12